作者
Nermine O Basta, Gail C Halliday, Guy Makin, Jillian Birch, Richard Feltbower, Nick Bown, Martin Elliott, Lucas Moreno, Giuseppe Barone, Andrew DJ Pearson, Peter W James, Deborah A Tweddle, Richard JQ McNally
发表日期
2016/10
期刊
British journal of cancer
卷号
115
期号
9
页码范围
1048-1057
出版商
Nature Publishing Group
简介
Background:
Despite therapeutic advances, survival following relapse for neuroblastoma patients remains poor. We investigated clinical and biological factors associated with length of progression-free and overall survival following relapse in UK neuroblastoma patients.
Methods:
All cases of relapsed neuroblastoma, diagnosed during 1990–2010, were identified from four Paediatric Oncology principal treatment centres. Kaplan–Meier and Cox regression analyses were used to calculate post-relapse overall survival (PROS), post-relapse progression-free survival (PRPFS) between relapse and further progression, and to investigate influencing factors.
Results:
One hundred eighty-nine cases were identified from case notes, 159 (84.0%) high risk and 17 (9.0%), unresectable, MYCN non-amplified (non-MNA) intermediate risk (IR). For high-risk patients diagnosed> 2000, median PROS was 8.4 months (interquartile …
学术搜索中的文章
NO Basta, GC Halliday, G Makin, J Birch, R Feltbower… - British journal of cancer, 2016